1 |
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Goto, M., Mochizuki, S. I., Tsuda, E., Morinaga, T., Udagawa, N., Takahashi, N., Suda, T. and Higashio, K. (1999) A novel molecular mechanism modulating osteoclast differentiation and function. Bone 25, 109-113.
DOI
ScienceOn
|
2 |
Zauli, G., Melloni, E., Capitani, S. and Secchiero, P. (2009). Role of full-length osteoprotegerin in tumor cell biology. Cell. Mol. Life Sci. 66, 841-851.
DOI
|
3 |
Park, M. K., Park, Y., Shim, J., Lee, H. J., Kim, S. and Lee, C. H. (2012) Novel involvement of leukotriene B(4) receptor 2 through ERK activation by PP2A down-regulation in leukotriene B(4)-induced keratin phosphorylation and reorganization of pancreatic cancer cells. Biochim. Biophys. Acta 1823, 2120-2129.
DOI
ScienceOn
|
4 |
Rosenthal, A. K., Derfus, B. A. and Henry, L. A. (1997) Transglutaminase activity in aging articular chondrocytes and articular cartilage vesicles. Arthritis Rheum. 40, 966-970.
DOI
|
5 |
Schneeweis, L. A., Willard, D. and Milla, M. E. (2005) Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J. Biol. Chem. 280, 41155-41164.
DOI
ScienceOn
|
6 |
Shipman, C. M. and Croucher, P. I. (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63, 912-916.
|
7 |
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R. and Boyle, W. J. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319.
DOI
ScienceOn
|
8 |
Speer, M. Y., Chien, Y. C., Quan, M., Yang, H. Y., Vali, H., McKee, M. D. and Giachelli, C. M. (2005) Smooth muscle cells defi cient in osteopontin have enhanced susceptibility to calcifi cation in vitro. Cardiovasc. Res. 66, 324-333.
DOI
ScienceOn
|
9 |
Thirunavukkarasu, K., Miles, R. R., Halladay, D. L., Yang, X., Galvin, R. J., Chandrasekhar, S., Martin, T. J. and Onyia, J. E. (2001) Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J. Biol. Chem. 276, 36241-36250.
DOI
ScienceOn
|
10 |
Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M. P., Deen, K. C., McLaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., Alnemri, E. S., Williams, W. V. and Doyle, M. L. (2000) Temperature-sensitive differential affi nity of TRAIL for its receptors. DR5 is the highest affi nity receptor. J. Biol. Chem. 275, 23319-23325.
DOI
ScienceOn
|
11 |
Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T. and Higashio, K. (1997) Isolation of a novel cytokine from human fi broblasts that specifi cally inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234, 137-142.
DOI
ScienceOn
|
12 |
Vidal, O. N., Sjogren, K., Eriksson, B. I., Ljunggren, O. and Ohlsson, C. (1998) Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem. Biophys. Res. Commun. 248, 696-700.
DOI
ScienceOn
|
13 |
Winther, S., Christensen, J. H., Flyvbjerg, A., Schmidt, E. B., Jorgensen, K. A., Skou-Jorgensen, H. and Svensson, M. (2013) Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. Clin Nephrol. [Epub ahead of print]
|
14 |
Kaartinen, M. T., Murshed, M., Karsenty, G. and McKee, M. D. (2007) Osteopontin upregulation and polymerization by transglutaminase 2 in calcifi ed arteries of Matrix Gla protein-defi cient mice. J. Histochem. Cytochem. 55, 375-386.
|
15 |
Lee, H. L., Park, M. K., Bae, H. C., Yoon, H. J., Kim, S. Y., Lee, C. H. and Lee, C. H. (2012) Transglutaminase-2 is involved in all-trans retinoic acid-induced invasion and matrix metalloproteinases expression of SH-SY5Y neuroblastoma cells via NF- pathway. Biomol. Ther. 20, 286-292.
DOI
ScienceOn
|
16 |
Kobayashi-Sakamoto, M., Hirose, K., Isogai, E. and Chiba, I. (2004) NF-kappaB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. Biochem. Biophys. Res. Commun. 315, 107-112.
DOI
ScienceOn
|
17 |
Kondo, H., Guo, J. and Bringhurst, F. R. (2002) Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J. Bone Miner. Res. 17, 1667-1679.
DOI
ScienceOn
|
18 |
Lambert, C., Oury, C., Dejardin, E., Chariot, A., Piette, J., Malaise, M., Merville, M. P. and Franchimont, N. (2007) Further insights in the mechanisms of interleukin-1beta stimulation of osteoprotegerin in osteoblast-like cells. J. Bone Miner. Res. 22, 1350-1361.
DOI
ScienceOn
|
19 |
Lorand, L. and Graham, R. M. (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 4, 140-156.
DOI
ScienceOn
|
20 |
McCarthy, H. S., Williams, J. H., Davie, M. W. and Marshall, M. J. (2009) Platelet-derived growth factor stimulates osteoprotegerin production in osteoblastic cells. J. Cell. Physiol. 218, 350-354.
DOI
ScienceOn
|
21 |
Mhaouty-Kodja, S. (2004) Ghalpha/tissue transglutaminase 2: an emer ging G protein in signal transduction. Biol. Cell 96, 363-367.
DOI
|
22 |
Mori, K., Le Goff, B., Berreur, M., Riet, A., Moreau, A., Blanchard, F., Chevalier, C., Guisle-Marsollier, I., Leger, J., Guicheux, J., Masson, M., Gouin, F., Redini, F. and Heymann, D. (2007) Human osteosarcoma cells express functional receptor activator of nuclear factorkappa B. J. Pathol. 211, 555-562.
DOI
ScienceOn
|
23 |
Cross, S. S., Yang, Z., Brown, N. J., Balasubramanian, S. P., Evans, C. A., Woodward, J. K., Neville-Webbe, H. L., Lippitt, J. M., Reed, M. W., Coleman, R. E. and Holen, I. (2006) Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int. J. Cancer 118, 1901-1908.
DOI
ScienceOn
|
24 |
Nurminskaya, M., Magee, C., Faverman, L. and Linsenmayer, T. F. (2003) Chondrocyte-derived transglutaminase promotes maturation of preosteoblasts in periosteal bone. Dev. Biol. 263, 139-152.
DOI
ScienceOn
|
25 |
Osorio, A., Ortega, E., Torres, J. M., Sanchez, P. and Ruiz-Requena, E. (2013) Biochemical markers of vascular calcifi cation in elderly hemodialysis patients. Mol. Cell. Biochem. 374, 21-27.
DOI
ScienceOn
|
26 |
Park, M. K., Lee, H. J., Shin, J., Noh, M., Kim, S. Y. and Lee, C. H. (2011) Novel participation of transglutaminase-2 through c-Jun Nterminal kinase activation in sphingosylphosphorylcholine-induced keratin reorganization of PANC-1 cells. Biochim. Biophys. Acta 1811, 1021-1029.
DOI
ScienceOn
|
27 |
De Toni, E. N., Thieme, S. E., Herbst, A., Behrens, A., Stieber, P., Jung, A., Blum, H., Goke, B. and Kolligs, F. T. (2008) OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin. Cancer Res. 14, 4713-4718.
DOI
ScienceOn
|
28 |
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C. and Young, P. R. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363-14367.
DOI
ScienceOn
|
29 |
Fisher, J. L., Thomas-Mudge, R. J., Elliott, J., Hards, D. K., Sims, N. A., Slavin, J., Martin, T. J. and Gillespie, M. T. (2006) Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 66, 3620-3628.
DOI
ScienceOn
|
30 |
Heath, D. J., Downes, S., Verderio, E. and Griffi n, M. (2001) Characterization of tissue transglutaminase in human osteoblast-like cells. J. Bone Miner. Res. 16, 1477-1485.
DOI
ScienceOn
|
31 |
Higashikawa, F., Eboshida, A. and Yokosaki, Y. (2007) Enhanced biological activity of polymeric osteopontin. FEBS Lett. 581, 2697-2701.
DOI
ScienceOn
|
32 |
Holen, I., Croucher, P. I., Hamdy, F. C. and Eaton, C. L. (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62, 1619-1623.
|
33 |
Johnson, K., Svensson, C. I., Etten, D. V., Ghosh, S. S., Murphy, A. N., Powell, H. C. and Terkeltaub, R. (2004) Mediation of spontaneous knee osteoarthritis by progressive chondrocyte ATP depletion in Hartley guinea pigs. Arthritis Rheum. 50, 1216-1225.
DOI
ScienceOn
|
34 |
Johnson, K. A., Polewski, M. and Terkeltaub, R. A. (2008) Transglutaminase 2 is central to induction of the arterial calcifi cation program by smooth muscle cells. Circ. Res. 102, 529-537.
DOI
ScienceOn
|
35 |
Augoulea, A., Vrachnis, N., Lambrinoudaki, I., Dafopoulos, K., Iliodromiti, Z., Daniilidis, A., Varras, M., Alexandrou, A., Deligeoroglou, E. and Creatsas, G. (2013) Osteoprotegerin as a marker of ath-erosclerosis in diabetic patients. Int. J. Endocrinol. 2013, 182060.
|
36 |
Brandstrom, H., Jonsson, K. B., Vidal, O., Ljunghall, S., Ohlsson, C. and Ljunggren, O. (1998) Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem. Biophys. Res. Commun. 248, 454-457.
DOI
ScienceOn
|
37 |
Johnson, K. A. and Terkeltaub, R. A. (2005) External GTP-bound transglutaminase 2 is a molecular switch for chondrocyte hypertrophic differentiation and calcifi cation. J. Biol. Chem. 280, 15004-15012.
DOI
ScienceOn
|